✦ LIBER ✦

Efficacy of peginterferon ALFA-2A (40KD) (PEGASYS) plud ribavirin for 24 weeks in genotype 1 patients with chronic hepatitis C followed by mono or combination therapy for 22 weeks: Preliminary analysis of an open, multicenter, randomized trial

✍ Scribed by J.P. Bronowicki; D. Ouzan; T. Asselah; H. Desmorat; J.P. Zarski; J. Foucher; M. Bourliere; C. Renous; A. Tran; P. Melin; C. Hezode; M. Chevallier; M. Bouvier; J.M. Pawlotsky; I. Lonjon-Domanec

Book ID: 117372384
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 278 KB
Volume: 38
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(03)80467-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

187 Efficacy and safety of 22 weeks of m

187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial

✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB